Schrodinger Inc at Goldman Sachs Byte-ology Conference (Virtual) Transcript
Welcome, everyone, and thank you for joining us for our first ever Byte-ology Conference on The Convergence of Biotechnology and Technology. Our first panel today is leveraging AI, machine learning and computational biology for drug development, and I'm joined by my colleague, Chris Shibutani, who covers the biopharma space. On this panel, we're pleased to have Exscientia, where we have Andrew Hopkins, CEO; Recursion Pharmaceuticals, Chris Gibson, CEO and Co-Founder; Relay Therapeutics, Sanjiv Patel; and Schrödinger, Karen Akinsanya, Head of Discovery R&D and Chief Biomedical Scientist.
With that, thank you, everyone, for joining us. And to start here, just for investors that may be unfamiliar, could you briefly introduce yourselves and give an overview of your company and platform, including what you would single out as a key advantage or differentiating factors? And Andrew, why don't we start with you?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
